These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34597977)

  • 1. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.
    Clarke WA; Chatelut E; Fotoohi AK; Larson RA; Martin JH; Mathijssen RHJ; Salamone SJ
    Eur J Cancer; 2021 Nov; 157():428-440. PubMed ID: 34597977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
    Verheijen RB; Yu H; Schellens JHM; Beijnen JH; Steeghs N; Huitema ADR
    Clin Pharmacol Ther; 2017 Nov; 102(5):765-776. PubMed ID: 28699160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    Zuidema S; Desar IME; van Erp NP; Kievit W
    Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.
    Beumer JH; Chu E; Allegra C; Tanigawara Y; Milano G; Diasio R; Kim TW; Mathijssen RH; Zhang L; Arnold D; Muneoka K; Boku N; Joerger M
    Clin Pharmacol Ther; 2019 Mar; 105(3):598-613. PubMed ID: 29923599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.
    Huang W; Li J; Qiu F; Wu X; Zhang J; Li X; Yao G; Zhu S
    J Clin Pharm Ther; 2020 Aug; 45(4):856-862. PubMed ID: 32479700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians.
    Schoretsanitis G; Paulzen M; Unterecker S; Schwarz M; Conca A; Zernig G; Gründer G; Haen E; Baumann P; Bergemann N; Clement HW; Domschke K; Eckermann G; Egberts K; Gerlach M; Greiner C; Havemann-Reinecke U; Hefner G; Helmer R; Janssen G; Jaquenoud-Sirot E; Laux G; Messer T; Mössner R; Müller MJ; Pfuhlmann B; Riederer P; Saria A; Schoppek B; Silva Gracia M; Stegmann B; Steimer W; Stingl JC; Uhr M; Ulrich S; Waschgler R; Zurek G; Hiemke C
    World J Biol Psychiatry; 2018 Apr; 19(3):162-174. PubMed ID: 29493375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
    Fahmy A; Hopkins AM; Sorich MJ; Rowland A
    Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
    [No Abstract]   [Full Text] [Related]  

  • 9. Gastrointestinal stromal tumor (GIST) and imatinib.
    Kubota T
    Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
    Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
    Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
    Reichardt P; Schlemmer M; Delgado Perez JR; Papai Z; Prausova J; Melichar B; Fumagalli E; Barone C; Bauer S; Pustowka A; Crippa S; Castellana R; Quiering C; Le Cesne A
    Oncol Res Treat; 2019; 42(12):629-635. PubMed ID: 31550719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
    Rutkowski P; Bylina E; Lugowska I; Teterycz P; Klimczak A; Streb J; Czarnecka AM; Osuch C
    J Geriatr Oncol; 2018 Sep; 9(5):520-525. PubMed ID: 29602734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate-induced lichenoid drug eruption.
    Penn EH; Chung HJ; Keller M
    Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].
    Yamaguchi H; Takasaki S; Kikuchi M; Kawasaki Y; Arai Y; Mano N
    Yakugaku Zasshi; 2019; 139(6):911-915. PubMed ID: 31155535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
    Turjap M; Juřica J; Demlová R
    Klin Onkol; 2015; 28(2):105-11. PubMed ID: 25882020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
    Hiemke C; Baumann P; Bergemann N; Conca A; Dietmaier O; Egberts K; Fric M; Gerlach M; Greiner C; Gründer G; Haen E; Havemann-Reinecke U; Jaquenoud Sirot E; Kirchherr H; Laux G; Lutz UC; Messer T; Müller MJ; Pfuhlmann B; Rambeck B; Riederer P; Schoppek B; Stingl J; Uhr M; Ulrich S; Waschgler R; Zernig G
    Pharmacopsychiatry; 2011 Sep; 44(6):195-235. PubMed ID: 22053351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.